Xencor, Inc. (NASDAQ:XNCR) Receives Average Rating of "Buy" from Analysts

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) has been given a consensus rating of "Buy" by the eight research firms that are covering the firm, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $33.86.

Several equities research analysts have recently weighed in on the company. StockNews.com cut Xencor from a "hold" rating to a "sell" rating in a research report on Friday, March 14th. William Blair assumed coverage on Xencor in a research report on Monday. They issued an "outperform" rating for the company. Finally, Wells Fargo & Company reduced their price objective on Xencor from $37.00 to $33.00 and set an "overweight" rating for the company in a research report on Friday, February 28th.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of XNCR. FMR LLC raised its stake in Xencor by 315.5% during the third quarter. FMR LLC now owns 16,764 shares of the biopharmaceutical company's stock worth $337,000 after acquiring an additional 12,729 shares in the last quarter. Jane Street Group LLC increased its stake in shares of Xencor by 18.6% in the third quarter. Jane Street Group LLC now owns 168,431 shares of the biopharmaceutical company's stock valued at $3,387,000 after buying an additional 26,473 shares in the last quarter. Barclays PLC increased its stake in shares of Xencor by 100.7% in the third quarter. Barclays PLC now owns 155,568 shares of the biopharmaceutical company's stock valued at $3,128,000 after buying an additional 78,066 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Xencor by 1.2% in the third quarter. Geode Capital Management LLC now owns 1,455,350 shares of the biopharmaceutical company's stock valued at $29,273,000 after buying an additional 17,658 shares in the last quarter. Finally, Sanctuary Advisors LLC acquired a new stake in shares of Xencor in the third quarter valued at $540,000.

Xencor Stock Up 4.8 %

Shares of NASDAQ:XNCR traded up $0.51 during midday trading on Friday, hitting $11.16. 73,552 shares of the stock were exchanged, compared to its average volume of 624,487. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. Xencor has a 52-week low of $7.16 and a 52-week high of $27.24. The business's fifty day simple moving average is $12.10 and its two-hundred day simple moving average is $18.60. The company has a market capitalization of $786.36 million, a PE ratio of -3.49 and a beta of 0.90.

Xencor (NASDAQ:XNCR - Get Free Report) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.19. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The company had revenue of $52.79 million for the quarter, compared to analyst estimates of $17.14 million. As a group, research analysts predict that Xencor will post -3.68 earnings per share for the current fiscal year.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.